Commercialization: Page 73
- 
                    
                    
                        
                    
                    
                    Registration and Launch: The Next Steps of a Long JourneyThe registration and launch phase is evolving like the rest of drug development, and the industry must evolve its practices along with it. One big aha moment for the industry is to understand that data, study reports, and other regulatory documents are not the end, but rather integral parts of th... By Robin Robinson • March 4, 2010
- 
                    
                    
                        
                    
                    
                    Phase III: Market PreparationHow the brand begins to be positioned across the spectrum of medical communications — specifically how the science behind the brand and trial results begin to be discussed at global and local congresses, from interactive and traditional exhibit stands to symposia, from posters to special social e... By Robin Robinson • March 4, 2010
- 
                    
                    
                        
                    
                    
                    Phase II: Testing Efficacy, Planning for MarketingPharmaceutical companies and their partners are working to address productivity and create efficiency in Phase II development. New types of trial designs, such as adaptive trials, are being considered as solutions to these perennial issues. “There are innovative ways in which biopharmaceutical co... By Denise Myshko • March 4, 2010
- 
                    
                    
                        
                    
                    
                    Phase I: Patient RecruitmentAccording to Peter Smith, Ph.D., senior VP, nonclinical development sciences at Millennium Pharmaceuticals: The Takeda Oncology Company, shortages in funding, manpower, and patient availability have created the proverbial perfect storm in the current clinical trial system. “The fact that traditio... By Denise Myshko • March 4, 2010
- 
                    
                    
                        
                    
                    
                    Talent PoolPharmaceutical POOL John DUCKER, APP Pharmaceuticals Dr. Julie GERBERDING, Merck Dr. Michael ROSENBLATT, Merck Sean NOLAN, Lundbeck Inc. Derica RICE, Lilly Biotechnology POOL Dr. Mark BAGARAZZI, Inovio Biomedical Hans BISHOP, Dendreon Suzanne CADDEN, ImmunoGen Dr. Thomas HOFSTAETTER, VaxInnate Dr... By PharmaVoice Team • March 4, 2010
- 
                    
                    
                        
                    
                    
                    E-mediaNew Electronic and Web-based Applications, Sites, and Technologies Featured Briefs: Perceptive Informatics Introduces E-Clinical Suite Elsevier Launches Online Resource Center for ARRA Updates Thomson Pharma Database Integrates Trial Protocol, Outcome Info Take Supply Chain Releases Multi-Tenant ... By PharmaVoice Team • March 4, 2010
- 
                    
                    
                        
                    
                    
                    What's NewNew Healthcare-related Products, Services, and Companies Featured Briefs: GxP Consulting Adds Statistical Analysis Support Former Wyeth VP Launches Petkus Communications Consultants GlobalHealth Provides Corporate Training, Degree Programs Newly Formed Durata Therapeutics Acquires Pfizer’s Vicuro... By PharmaVoice Team • March 4, 2010
- 
                    
                    
                        
                    
                    
                    PharmaTraxSales, Marketing, and R&D Trends from Industry Analysts Featured Briefs: Process Inefficiencies Cause $11 Billion in Annual Pharma Revenue Leakage Sidebar: Key Findings of Revenue Leakage Study Drug Companies Still Under Pressure to Increase Pace of Development Sidebar: Key Near-Term Trends i... By PharmaVoice Team • March 4, 2010
- 
                    
                    
                        
                    
                    
                    UpfrontAccording to industry experts, the impact of the updated REMS policy in 2007 has had limited impact on the industry thus far. The FDA was granted expanded authority to require REMS (risk evaluation and mitigation strategies) for new drug applications or for existing drugs where the FDA has determ... By PharmaVoice Team • March 4, 2010
- 
                    
                    
                        
                    
                    
                    Opportunities in Oncology DevelopmentAdvances in cancer research, knowledge, treatment options, and awareness have increased tremendously in the past 25 years. Rates of new diagnoses and deaths from all cancers have declined significantly for men and women overall and for most racial and ethnic populations in the United States, acco... By PharmaVoice Team • Jan. 28, 2010
- 
                    
                    
                        
                    
                    
                    Help Wanted: Pharma BloggersSocial media specialist positions are growing exponentially — just Google the term to view the jobs that pop up. Many colleges and universities are now offering degrees in how to write, publish, and strategize in this new media field. Hospitals, clinics, and other healthcare organizations have en... By Robin Robinson • Jan. 26, 2010
- 
                    
                    
                        
                    
                    
                    A 360-Degree View of E-Patient ConnectionsHealthcare information technology has created the platform for the exchange, collection, and documentation of health data and information, but it is up to the crucial players — patients, physicians, pharma companies, and service providers — to make e-connections work. The patient, the physician, ... By PharmaVoice Team • Jan. 26, 2010
- 
                    
                    
                        
                    
                    
                    Talent PoolBiotechnology POOL Dr. Paul LAMMERS Mirna Appoints Chief Executive Mirna Therapeutics has named Paul Lammers, M.D., president and CEO. As head of Mirna, Dr. Lammers is responsible for driving the company’s discoveries in the field of microRNA (miRNA) into the clinic. Dr. Lammers was previously pr... By PharmaVoice Team • Jan. 26, 2010
- 
                    
                    
                        
                    
                    
                    E-mediaNew Electronic and Web-based Applications, Sites, and Technologies Featured Briefs: IntraLinks, Adobe Collaborate on Data-Capture Solutions for Clinical Trials Maestro eLearning Creates e-Learning Library Deloitte Recap Helps Biopharma Executives Make Portfolio Decisions Thomson Reuters Unveil... By PharmaVoice Team • Jan. 26, 2010
- 
                    
                    
                        
                    
                    
                    What's NewNew Healthcare-related Products, Services, and Companies Featured Briefs: Pharma Industry Veteran Launches Online Recruitment Site FlightPath Enables Interactive Commercialization Planning Expanded SDI Media Services Measure Pharma Ad Campaign ROI New Team Aligns Parexel Experts With Biopharm... By PharmaVoice Team • Jan. 25, 2010
- 
                    
                    
                        
                    
                    
                    PharmaTraxSales, Marketing, and R&D Trends from Industry Analysts Featured Briefs: Companies Advised to Communicate with Payers Earlier in Drug Development Sidebar: Average Allocation of a Managed Markets Department’s Personnel Pharma Companies Add Employer Market to the Mix Sidebar: Employer Programs... By PharmaVoice Team • Jan. 25, 2010
- 
                    
                    
                        
                    
                    
                    UpfrontHonors and Awards G&A Receives Recognition The Rx Club presented Goble & Associates (G&A) with nine Awards of Excellence for a variety of ad campaigns, sales aids, launch campaigns, patient education brochures, and Web sites. In addition, G&A received two Gold and five Silver Awa... By PharmaVoice Team • Jan. 25, 2010
- 
                    
                    
                        
                    
                    
                    Brand ChampionsThe role of the is being played by branding companies, advertising agencies,by the companies that are in charge of producing materials and giving strategic advice to pharmaceutical companies.There are few companies that have a brand champion. Vince Parry TOO OFTEN BRANDING IS MISTAKEN FOR AN ADVE... By PharmaVoice Team • Jan. 18, 2010
- 
                    
                    
                        
                    
                    
                    No Pain, Big GainDaily injections are a painful way of life for an estimated 3.7 mil lion Americans who are insulin dependent diabetics. The condi tion, characterized by high blood sugar levels that result from defects in the body’s ability to produce and/or use insulin, is the fifth leading cause of death by dis... By PharmaVoice Team • Jan. 18, 2010
- 
                    
                    
                        
                    
                    
                    The Patient PipelineCLINICAL TRIAL RECRUITMENT AND ENROLLMENT EFFORTS ARE OFTEN NOT GIVEN HIGH PRIORITY, causing costly delays in the develop ment of new drugs. Unfortunately, there are no quick fixes, but companies are beginning to institute wellthought out and designed processes to bring the right patients to the ... By PharmaVoice Team • Jan. 18, 2010
- 
                    
                    
                        
                    
                    
                    Talent PoolPharma POOL Mark BOOTH Takeda Pharmaceuticals North America Names President Takeda Pharmaceuticals North America Inc. (TPNA), a wholly owned subsidiary of Takeda Chemical Industries Ltd., has restructured its senior executive team and named Mark Booth president. Mr. Booth, an 18year veteran of th... By PharmaVoice Team • Jan. 14, 2010
- 
                    
                    
                        
                    
                    
                    PharmaTraxSALES, MARKETING, AND R&D TRENDS AFFECTING THE HEALTHCARE INDUSTRY NestEggz Survey Suggests PATIENTS WHO SAVE ON PRESCRIPTIONS TAKE THEIR MEDICATION Almost 90% of cholesterol patients enrolled in NestEggz were found to take their medication daily, almost double the national average.NestEggz,a... By PharmaVoice Team • Jan. 14, 2010
- 
                    
                    
                        
                    
                    
                    For Art's SakeCatchy, creative, and memorable are three words to describe this month’s selection of standout creative executions. Two of the ad campaigns, Viagra and Glucotrol XL, were executed by Cline, Davis &Mann on behalf of client Pfizer Inc. The first of the ads was cre ated for the launch of Viagra.... By PharmaVoice Team • Jan. 14, 2010
- 
                    
                    
                        
                    
                    
                    Pharma OutletFor the first time since the Food and Drug Administration lessened restrictions on direct to consumer pharmaceutical advertisements in 1996, there is a significant slowing in direct to consumer advertising expenditures. From 1996 to 2000, directtoconsumer advertising spending grew more than three... By Susan Hempstead • Jan. 14, 2010
- 
                    
                    
                        
                    
                    
                    What's on Your Mind: OpinionsThe economy In my opinion, the biggest impact on the industry has been the fallout from the economic downturn. A climate of near paralysis has seized much of the industry and I don’t expect that climate to change much until well into 2003. The uncertainty of the timing of the eco nomic turnaround... By PharmaVoice Team • Jan. 14, 2010
 
    
        
     
                
                